Application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone

The invention relates to an application of mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine and prednisone in preparation of a medicine for treating peripheral T cell lymphoma (PTCL). The PTCL is preferably selected from PTCL subjected to primary treatment. On the basis, other first-line and second-line medicines for treating PTCL can be further used. A method of treating PTCL by administering to a patient a therapeutically effective amount of a liposome of mitoxantrone hydrochloride and cyclophosphamide, vincristine, and prednisone. The combined application of the medicine is safe and tolerant, has small toxic and side effects, and can obtain a higher total objective remission rate (ORR) in the primary treatment of PTCL patients. 盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松在制备用于治疗外周T细胞淋巴瘤(PTCL)的药物中的用途。所述PTCL优选初治的PTCL。还可在上述基础上进一步使用其他治疗PTCL的一线、二线药物。一种治疗PTCL的方法，所述方法为给予患者治疗有效量的盐酸米托蒽醌脂质体和环磷酰胺、长春新碱及强的松。该药物的联合施用安全耐受，毒副作用小，并且能够在初治PTCL患者中获得较高的总客观缓解率(ORR)。